Percutaneous aspiration thromboembolectomy.

Starck, E; McDermott, John C.; Crummy, Andrew B.; Turnipseed, William D.; Acher, Charles W.; Burgess, John H.

doi:10.1148/radiology.156.1.3159042

Cited by 163 publications

(48 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recently, percutaneous thrombectomy methods alone or combined with CDT have been widely used as an effective endovascular method for thrombus removal. Compared with CDT, percutaneous thrombectomy methods are able to remove the thrombus more rapidly without the risk of bleeding complication (17,(20)(21)(22)(23)(24)(26)(27)(28)(29). Vedantham et al (20) found that the use of adjunctive percutaneous mechanical thrombectomy to augment CDT provides comparable procedural success and may reduce thrombolytic dose requirements and infusion times.…”

Section: Discussionmentioning

confidence: 99%

“…Vedantham et al (20) found that the use of adjunctive percutaneous mechanical thrombectomy to augment CDT provides comparable procedural success and may reduce thrombolytic dose requirements and infusion times. PAT has been successfully used alone or in combination with local thrombolytic infusion to remove thromboembolic material from limb arteries (27,28). PAT is a cheap and simple method.…”

Section: Discussionmentioning

confidence: 99%

“…It proposes a rapid and effective way to remove thrombus. Moreover, it can be used in almost every patient who is unresponsive to anticoagulation therapy or has a contraindication to thrombolysis (22,(27)(28)(29). PAT has also been effectively used alone or in combination with thrombolysis to treat lower extremity DVT (22,29).…”

Section: Discussionmentioning

confidence: 99%

See 2 more Smart Citations

Endovascular treatment of iliofemoral deep vein thrombosis in pregnancy using US-guided percutaneous aspiration thrombectomy

Gedikoglu¹,

Oğuzkurt²

2017

Diagn Interv Radiol

View full text Add to dashboard Cite

P regnancy is a risk factor for venous thromboembolism (VTE) and the risk is highest in the postpartum period (1, 2). Anticoagulants are very effective in the prevention of pulmonary embolism (PE) and recurrent thrombosis, but the treatment of deep vein thrombosis (DVT) remains a challenge, because lysis of the thrombus formed in the deep veins is slow and frequently inadequate as a therapy (3, 4). Complete or significant lysis occurs only in 4% of patients treated with heparin alone (3). Persistence of thrombus within deep veins leads to venous hypertension, which is ultimately the cause of post-thrombotic syndrome (PTS) and late disability in 20% to 50% of patients. PTS is a conglomerate of lifestyle-limiting symptoms that commonly includes chronic leg pain and swelling, heaviness, and/or fatigue, venous claudication, stasis dermatitis, and in advanced cases skin ulcerations due to valvular incompetence accompanied by persistent venous outflow obstruction (4-8). Pregnant women are generally younger than other women in the general population, and they likely suffer a more severe form of PTS for a much longer time.Anticoagulants have been the standard therapy of DVT in pregnant women because of concerns related to administering contrast agent, exposing the fetus to radiation during interventional radiologic procedures, and bleeding complication associated with thrombolysis (9). Nonetheless, there are a few publications describing thrombolytic therapy of DVT with good success during pregnancy and peri-or postpartum period (10-13). In a previous study (14), a pregnant woman with DVT was treated using percutaneous mechanical thrombectomy under venographic guidance with contrast agent. Percutaneous aspiration thrombectomy (PAT) with or without fluoroscopy guidance in preg- 71From the Department of Radiology (M.G. 

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Endovascular treatment of iliofemoral deep vein thrombosis in pregnancy using US-guided percutaneous aspiration thrombectomy

Gedikoglu¹,

Oğuzkurt²

2017

Diagn Interv Radiol

View full text Add to dashboard Cite

show abstract

“…Manual aspiration thrombectomy (MAT) via large lumen catheters was the fi rst method of endovascular arterial thrombus extraction [52,53]. Typically, it is utilised as an adjunctive procedure in patients with thromboembolic complications after endovascular procedures.…”

Section: Manual Thrombus Aspirationmentioning

confidence: 99%

Treatment of acute lower limb ischaemia

Łukasiewicz

2016

Vasa

View full text Add to dashboard Cite

Summary: Acute lower limb ischaemia poses a major threat to limb survival. For many years surgical thromboembolectomy was the mainstay of treatment. Recent years have brought an endovascular revolution in the management of acute lower limb ischaemia. A wide range of endovascular procedures can nowadays be employed, providing results at least as good as the traditional surgical approach. This paper is an overview of currently utilised endovascular options as well as recent modifi cations of standard surgical techniques.

show abstract

“…It often reveals transversal lesions in the distal part of the occlusion, facilitating a direct approach to secondary narrowing of the affected vessel (working Party on Thrombolysis, 2003). The first experiences with this method were published by Starck (1985) and it has been a well accepted method ever since, especially for removing acute, fresh thrombi, using a thin-walled end-hole catheter, connected to a syringe, which helps to create suction pressure. The clot with all remnants is subsequently sucked through the catheter into the syringe.…”

Section: Percutaneous Aspiration Thromboembolectomy (Pat)mentioning

confidence: 99%

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Dvořák¹,

Vlašín²,

Dvorakova³

et al. 2010

Vet. Med. - Czech

View full text Add to dashboard Cite

Arterial occlusion due to thrombosis caused by ruptured atherosclerotic plaques (Baba et al., 1975) has been recognized as a major cause of morbidity and mortality in western populations. Thrombosis may occur in various sections of arterial circulation, peripheral arteries of the limbs, coronary arteries, brain arteries, or both major and minor vessels within the abdominal cavity. The ultimate consequence is varying degrees of organ failure, mostly of ischemic origin. Arterial thrombosis represents a continuous problem, debilitating patients and decreasing their quality of life. Moreover, along with chronic heart failure, it can significantly decrease patient life expectancy. Arterial thrombosis results in ischemia, with serious systemic consequences, such as metabolic breakdown. The major goal of treatment remains fast and efficient recanalization -surgical, interventional or thrombolytic. To be able to prevent acute reocclusion with severe consequences (rhabdomyolysis, compartment syndrome, excessive tissue necrosis leading to limb amputation, etc.), several adjunctive treatment regimens have been advocated. Among others, thrombin inhibitors and platelet inhibitors have been widely used for both prophylaxis and adjunctive treatment. Direct thrombin inhibitors and antithrombin stimulators have been recognized as typical antithrombotic drugs. Direct (antithrombin-independent) thrombin inhibitors can be divided into two main categories: monovalent, active site inhibitors (argatroban, efegatran, inovastan, melagatran) and bivalent (hirudin, hirugen, hirulog, bivalirudin), while antithrombin stimulators represent standard (unfractionated) heparin (UFH) and its depolymerizing products -low molecular weight heparins (LMWH's). Recently, a clear change in the main use of heparin, as well as low-molecular weight heparins has been advocated representing a shift from treatment and prophylaxis of deep vein thrombosis to prophylaxis of thromboembolic disease following vascular, cardiovascular or orthopedic surgery, treatment of unstable angina and prevention of acute myocardial infarction. The main effect of heparins lies in their anticoagulant activity. Heparins are involved in different pathways of the coagulation cascade with anticoagulant, antithrombotic, profibrinolytic, anti-aggregative, as well as anti-inflammatory effects. Moreover, there is a little doubt about their anti-proliferative and anti-ischemic activity (Penka and Bulikova, 2006). Unlike standard heparin, low-molecular weight heparins do not affect the patient's general coagulation profile. Obviously, the difference in molecular weight results in different pharmacokinetic and pharmacodynamic properties of the agents.Key words: coagulation; arterial thrombosis; standard heparin; low-molecular weight heparins List of abbreviations ABI = axillary/...index, t-PA = tissue-type plasminogen activator, ADP = adenosin diphosphate, AG = angiography, AMI = acute myocardial infarction, APSAC = acylated plasminogen streptokinase activator complex, APTT = acti...

show abstract

Percutaneous aspiration thromboembolectomy.

Cited by 163 publications

References 0 publications

Endovascular treatment of iliofemoral deep vein thrombosis in pregnancy using US-guided percutaneous aspiration thrombectomy

Endovascular treatment of iliofemoral deep vein thrombosis in pregnancy using US-guided percutaneous aspiration thrombectomy

Treatment of acute lower limb ischaemia

Heparin and its derivatives in the treatment of arterial thrombosis: a review

Contact Info

Product

Resources

About